Attached files

file filename
EX-99.1 - PRESS RELEASE - PERNIX THERAPEUTICS HOLDINGS, INC.ptx_ex991.htm


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): November 12, 2013
 
PERNIX THERAPEUTICS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)

Maryland
 
001-14494
 
33-0724736
(State or other jurisdiction
 of incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)

10863 Rockley Road
Houston, Texas
 
77099
(Address of principal executive offices)
 
(Zip Code)

 
Registrant’s telephone number, including area code: (832) 934-1825
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 

o
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
o
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
o
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
o
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 


 
 
 
 
 
 
Item 2.02
Results of Operations and Financial Condition
 
On November 12, 2013, Pernix Therapeutics Holdings, Inc. (the “Company”) issued a press release reporting its results for the third quarter ended September 30, 2013. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

The information in this Item 2.02 (and in Item 9.01) shall be deemed to be furnished to the Securities and Exchange Commission but not filed, and shall not be deemed to be incorporated by reference into any filings by the Company under the Securities Act of 1933, as amended, unless the Company expressly states otherwise in such filing.

Item 9.01
Financial Statements and Exhibits

(d)      Exhibits.
 
Exhibit Number
 
 
Description
     
99.1
 
Press release by Pernix Therapeutics Holdings, Inc. dated November 12, 2013 reporting its results for the third quarter ended September 30, 2013

 
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
PERNIX THERAPEUTICS HOLDINGS, INC.
 
       
 
By:
/s/ Tracy Clifford  
   
Tracy Clifford
 
    Principal Financial and Accounting Officer  
       
 

 
Dated:           November 12, 2013